Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Emergent Biosolutions Inc. (EBS : NYSE)

• Company Description    Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions. Number of Employees: 900

• Price / Volume Information    Yesterday's Closing Price: $10.16 Daily Weekly Monthly 20 Day Moving Average: 1,418,353 shares Shares Outstanding: 52.52 (millions) Market Capitalization: $533.60 (millions) Beta: 2.05 52 Week High: $13.41 52 Week Low: $4.02 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.02% 9.08% 12 Week 14.93% 10.17% Year To Date 6.28% -7.10%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 300 Professional Drive - GAITHERSBURG,MD 20879 USA ph: 240-631-3200 fax: 301-795-1899 lindahlr@ebsi.com http://www.emergentbiosolutions.com

• General Corporate Information    Officers Joseph C. Papa - Chief Executive Officer;President and Director Richard S. Lindahl - Executive Vice President and Chief Financial Offic Zsolt Harsanyi - Director Sujata Dayal - Director Donald DeGolyer - Director Peer Information Emergent Biosolutions Inc. (CORR.) Emergent Biosolutions Inc. (RSPI) Emergent Biosolutions Inc. (CGXP) Emergent Biosolutions Inc. (BGEN) Emergent Biosolutions Inc. (GTBP) Emergent Biosolutions Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29089Q105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/02/26 Share - Related Items Shares Outstanding: 52.52 Most Recent Split Date: (:1) Beta: 2.05 Market Capitalization: $533.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.64 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.19 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/02/26

• Fundamental Ratios P/E Current FY Estimate: 8.54 Trailing 12 Months: 5.13 PEG Ratio: - Price Ratios Price/Book: 0.92 Price/Cash Flow: 5.29 Price / Sales: 0.68 EPS Growth vs. Year Ago Period: -22.63% vs. Previous Quarter: 562.50% Sales Growth vs. Year Ago Period: -21.34% vs. Previous Quarter: 64.02% ROE 09/30/25 - 20.85 06/30/25 - 24.63 03/31/25 - -0.52 ROA 09/30/25 - 7.89 06/30/25 - 8.97 03/31/25 - -0.17 Current Ratio 09/30/25 - 5.76 06/30/25 - 5.66 03/31/25 - 6.32 Quick Ratio 09/30/25 - 3.15 06/30/25 - 3.00 03/31/25 - 3.51 Operating Margin 09/30/25 - 14.23 06/30/25 - 15.04 03/31/25 - -0.26 Net Margin 09/30/25 - 9.62 06/30/25 - 16.38 03/31/25 - -13.63 Pre-Tax Margin 09/30/25 - 13.42 06/30/25 - 22.39 03/31/25 - -6.45 Book Value 09/30/25 - 11.09 06/30/25 - 10.05 03/31/25 - 10.17 Inventory Turnover 09/30/25 - 1.09 06/30/25 - 1.23 03/31/25 - 1.98 Debt-to-Equity 09/30/25 - 1.14 06/30/25 - 1.25 03/31/25 - 1.20 Debt-to-Capital 09/30/25 - 53.24 06/30/25 - 55.47 03/31/25 - 54.64

Powered by Zacks Investment Research ©